#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ovarian cancer stage IV Liposarcoma Tuberous sclerosis complex Malignant glioma Staphylococcal infection Mitochondrial encephalomyopathy Friedreich's ataxia Mucopolysaccharidosis I VEXAS syndrome Short stature homeobox gene mutation Acute myeloid leukaemia refractory Anaplastic thyroid cancer Antisynthetase syndrome Vascular malformation Malignant peritoneal neoplasm More trials…

    Learn about Rare Diseases

    Activated PI3 kinase delta syndrome – Life with Disease Hereditary optic atrophy – Life with Disease Prolymphocytic leukaemia – Diagnostics Kearns-Sayre syndrome – Diagnostics Systemic mastocytosis Familial amyotrophic lateral sclerosis – Life with Disease KBG syndrome – Life with Disease Hairy cell leukaemia recurrent – Treatment Netherton’s syndrome – Life with Disease Vascular malformation – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tabelecleucel SRSD107 Bevacizumab Nicotine Mogamulizumab Lenalidomide Valoctocogene Roxaparvovec Doxorubicin Hydrochloride Nelivaptan Oxybuprocaine Hydrochloride Valganciclovir Hydrochloride Oxytocin Synthetic Platelet Concentrate Tarlatamab Oxogluric Acid Blu-451 Fosaprepitant Azd7798 BMS-986470 Thiamine More therapies…

    Learn about Your Condition

    Rett syndrome Vasospasm Chronic granulomatous disease Acne Bile duct cancer Pancreatic carcinoma stage IV Dent's disease Pulmonary embolism Amnestic disorder Follicular lymphoma stage IV Angiosarcoma recurrent Catatonia Bronchiectasis Relapsing multiple sclerosis Liver disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Pauls Stradins Clinical University Hospital

Pauls Stradins Clinical University Hospital

Pliiccx Iqjn 1ti Ruprj 1qnud Licyic

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

    Recruiting

    3 1 1
    Investigated Drugs:
    • Depemokimab
    • Salbutamol Sulfate
    Austria Bulgaria Czechia Germany Greece Italy +2

  • Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

    Recruiting

    3 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Latvia Lithuania Poland Slovakia +1

  • Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

    Recruiting

    4 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • LUNSEKIMIG
    Belgium Denmark Estonia Finland France Germany +7

  • Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Croatia Czechia France Greece Hungary Italy +5

  • Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Aflibercept
    Estonia Germany Latvia Poland Spain

  • GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

    Recruiting

    3 1
    Bulgaria Croatia Czechia Germany Greece Hungary +4

  • A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Igg-Like T Cell Engager Binding To Dll3 And Cd3
    • Atezolizumab
    • Carboplatin
    Austria Belgium Bulgaria Czechia Estonia Finland +14

  • Long-Term Study of Imeroprubart in Adults With Graves’ Disease

    Recruiting

    2 1 1
    Investigated Drugs:
    • IMEROPRUBART
    Belgium Bulgaria Czechia Germany Greece Hungary +5

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Hydroxocobalamin
    • Sotorasib
    • Betamethasone Sodium Phosphate Ph. Eur
    Austria Belgium Bulgaria Czechia Denmark France +11

  • A study to evaluate the effectiveness and safety of REGN13335 in adults with pulmonary arterial hypertension

    Recruiting

    2 1
    Investigated Drugs:
    • HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B
    Belgium Czechia France Germany Latvia Poland +1
1 2 3 … 15
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!